Passage Bio (PASG)
(Delayed Data from NSDQ)
$1.32 USD
+0.10 (8.20%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $1.32 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PASG 1.32 +0.10(8.20%)
Will PASG be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for PASG based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PASG
Passage Bio, Inc. (PASG) Is Up 24.26% in One Week: What You Should Know
PASG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for PASG
Passage Bio to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Analysts’ Top Healthcare Picks: Wave Life Sciences (WVE), Passage Bio (PASG)
Analysts Are Bullish on Top Healthcare Stocks: Quanterix (QTRX), Passage Bio (PASG)
PASG Stock Earnings: Passage Bio Beats EPS for Q4 2023
New Innovation / R&D Risk for Passage Bio, Inc. – What’s the Latest?